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Objectives: In many countries, future unrelated medical costs occurring during life-years gained are excluded from economic
evaluation, and benefits of unrelated medical care are implicitly included, leading to life-extending interventions being
disproportionately favored over quality of life-improving interventions. This article provides a standardized framework for
the inclusion of future unrelated medical costs and demonstrates how this framework can be applied in England and Wales.
Methods: Data sources are combined to construct estimates of per-capita National Health Service spending by age, sex, and
time to death, and a framework is developed for adjusting these estimates for costs of related diseases. Using survival curves
from 3 empirical examples illustrates how our estimates for unrelated National Health Service spending can be used to
include unrelated medical costs in cost-effectiveness analysis and the impact depending on age, life-years gained, and
baseline costs of the target group.
Results: Our results show that including future unrelated medical costs is feasible and standardizable. Empirical examples
show that this inclusion leads to an increase in the ICER of between 7% and 13%.
Conclusions: This article contributes to the methodology debate over unrelated costs and how to systematically include them
in economic evaluation. Results show that it is both important and possible to include future unrelated medical costs.
Keywords: economic evaluation, future costs, NICE, unit costs.
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Population aging and its relationship with healthcare has not
escaped attention in the research community.1 A concern
regarding the treatment of aging in economic evaluation is that
extending life leads to additional consumption of healthcare.2 A
patient who receives a medical intervention providing them
with additional life-years will continue consuming healthcare in
the life-years gained (LYG). For example, a patient who is
treated for a heart attack and survives may, during their LYG,
get cancer. The costs in the LYG that are directly related to the
disease being treated, for example, cardiovascular disease, are
referred to as future related medical costs. Future unrelated
medical costs, such as cancer treatment costs in the LYG, are a
consequence of the life-extending nature of the treatment.3
Studies show that increasing hospital survival leads to an in-
crease in emergency admissions in patients whose lives were
saved.4 It is likely that this increase in admissions leads to an
increase in medical costs.
The inclusion of future unrelated medical costs is a topic of
debate in health technology assessment, with the United Statesss correspondence to: Meg Perry-Duxbury, MSc, P.O. Box 1738, 3000 DR Ro
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cess article under the CC BY license (http://creativecommons.org/licenses/band The Netherlands recommending5 or requiring6 the inclusion
of future unrelated medical costs in economic evaluation.
Furthermore, researchers have previously argued that future un-
related medical costs should be stipulated to be included in
guidelines for England and Wales, provided by the National
Institute for Clinical Excellence (NICE),7,8 an amendment to NICE’s
current guidelines, which state that any costs considered unre-
lated to the condition or technology of interest should be
excluded.9
There are several arguments for the inclusion of future unre-
lated medical costs. First, to the extent that unrelated treatments
are a firm commitment made by the healthcare system (this may
be less applicable in countries with less stable and comprehensive
benefits packages, such as low- to middle-income countries)10 and
given a fixed healthcare budget, extending life and thereby
increasing future unrelated medical costs leads to health oppor-
tunity costs by leaving less budget for others in added life-years.
By excluding future unrelated medical costs, the opportunity
cost of these life-extending interventions is underestimated.11
Second, excluding future unrelated costs generated by life-
extending interventions indirectly introduces a bias againsttterdam, The Netherlands. Email: perryduxbury@eshpm.eur.nl
Health Economics and Outcomes Research. Published by Elsevier Inc. This is an
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1028 VALUE IN HEALTH AUGUST 2020quality-of-life improving interventions, which do not add future
costs. Third, estimates of quality-of-life and life expectancy are
typically obtained from people receiving unrelated care; excluding
costs and including benefits of unrelated future medical care is
inconsistent.3
There is a pragmatic argument against the inclusion of future
costs worth discussing here: the argument that future costs for all
diseases would need to be separately modeled, thus the estima-
tion of these costs is too complex to be carried out for every
economic evaluation.12–14 Nevertheless, there are methods facili-
tating the estimation of future unrelated medical costs,2,15 which
have been applied in several countries including England and
Wales.16–19 What all these methods have in common is that rather
than predicting the risk of all unrelated diseases and connecting
these predictions to costs, they take per-capita costs by age and
sex that comprise all medical spending as a starting point. Per-
capita costs are then multiplied by survival curves to estimate
incremental future unrelated medical costs. To avoid double-
counting costs of related diseases, some studies have adjusted
these per-capita costs for related diseases.17,20 A further issue
concerning aging and economic evaluation is that much of the
increase in healthcare costs attributed to aging can be attributed
to someone being in their last year of life. This is referred to as
time to death (TTD)21 and is most visible in hospital inpatient care,
given the high cost of many inpatient treatments.22,23 Previous
studies have also considered that health spending is centered in
the last phase of life, concluding that future unrelated medical
costs are overestimated if one ignores TTD.15,18Methods
Conceptual Model
In economic evaluations for NICE, an ICER is calculated to
provide a measure of an intervention’s cost-effectiveness against
the threshold, k. The ICER in its basic form is written as DCostsDQALYs,
where the change in costs refers to a change only in related
medical costs. Nevertheless, as established in the introduction,
interventions that extend survival implicitly generate future un-
related medical costs in the additional LYG. Therefore, the decision
rule for cost-effectiveness, from a healthcare perspective, can be
written as:
D½L 3 ðCr 1 CuÞ 
D½L 3 Q  , k (1)
L stands for life-years, Q for quality of life, and Cr and Cu for
related medical costs and unrelated medical costs. krepresents the
cost-effectiveness threshold. Given that unrelated medical costs
conditional on survival are independent of the intervention
(DCu ¼ 0), equation 1 is rewritten as:
DðL 3 CrÞ 1 DL3 Cu
D½L 3 Q  , k (2)
The difference in unrelated costs between intervention and
comparator is solely dependent on the difference in life-years.
The variable of interest is the incremental future unrelated
medical costs DL 3 Cu, which is denoted as Dlhcu. The simplest
way of estimating Dlhcu is to use age-specific per-capita healthcare
spending and to multiply these with survivor curves in the







lðaÞ 3 acðaÞ (3)Where l’(a) and l(a) denote the probability of surviving to age a in
the treatment and comparator scenario, respectively. acðaÞ in-
dicates total annual health spending per capita at age a. This
method has been proposed by Meltzer (1997)2 and has the
advantage that it is simple and data requirements are modest.
Nevertheless, if lifetime related costs are already included, then
using equation 3 leads to double-counting of related costs. To
overcome this, per-capita health spending should be corrected so
that only per-capita costs of unrelated diseases (denoted acuðaÞ)







lðaÞ 3 acuðaÞ (4)
Standardizing estimates
To remove the double-counted related healthcare costs, per-
capita unrelated costs can be calculated in a standardized
manner using information on the related costs included in the
original evaluation. To do this, total per-capita costs can be treated
simply as the sum of per-capita related and unrelated costs:
acuðaÞ¼ acðaÞ 2 acrðaÞ (5)
Per-capita related costs are often not directly available. Never-
theless, they can be seen as the product of disease prevalence of
disease r (denoted pða; rÞÞ, and per costs per patient for disease r
related costs (denoted acrða j r Þ).
acrðaÞ¼pða; rÞ 3 acrða j r Þ (6)
Equation 6 provides a framework to adjust average costs per
capita for costs of usual care for related diseases that often are
included in an economic evaluation but also are part of ac(a).
Related costs are anticipated to be small when evaluating most
interventions, given the relatively small number of people with
each disease in a population. Exceptions are particularly likely in
some public health interventions.17,24 Note that when end-of-life
costs are provided in an economic evaluation, these can also be
used to adjust per-capita costs, because per patient costs for dis-
ease r are a weighted average of end-of-life costs and costs for
those who are not in their last year of life:
acrða j r Þ ¼ ½12mða j rÞ3 scrða j rÞ 1 mða j rÞ 3 dcrða j rÞ (7)
Here, mða j rÞ denotes the mortality rate at age a conditional on
having disease r, dcrða j rÞ denotes end-of-life/decedent costs for
disease r conditional on having disease r, and scrða j rÞ represents
survivor costs, conditional on having the disease.
It is always a possibility that the participants in the interven-
tion trial are not average consumers of healthcare, for example
owing to comorbidities. Some diseases are known to be causally
related, and thus it is expected that average healthcare costs for
those with comorbidities would be higher than those of an
average individual. In these cases, unrelated costs can be updated
by obtaining comorbidity-specific costs that are not defined as
related costs, separately for survivors and decedents if possible,
and then adding these comorbidity costs to the unrelated cost.
It can also be beneficial to adjust for TTD, by disaggregating
individual future unrelated medical costs, which is labeled as lhcu,
into the sum of survivor, scuðaÞ; and decedent, dcuðnÞ, unrelated
medical costs, where survivor costs are costs at each age, a,
excluding the age at which the individual dies and decedent costs
are costs incurred in the last year of life (equation 8). b is the age at
which the intervention is implemented, and n is the age at which
the individual dies.
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Xn 2 1
a ¼ b
scuðaÞ 1 dcuðnÞ (8)
Average unrelated medical costs by age therefore need to be split
into survival costs, scðaÞ, and decedent costs, dcðaÞ. This is shown
in equations 9 to 11. Average medical costs, acðaÞ, are a weighted
average of decedent and survivor costs in a certain year. Total
survivor and decedent costs from the provided average costs are
calculated using mortality rates, m, and the ratio of medical costs
between those dying and surviving, vðaÞmvðaÞ. This decedent-
survivor cost ratio is taken from previous literature, in which
healthcare expenditure panel data is combined with TTD and age
information to estimate these ratios.23 Given equations 9 and 10,
which provide the decomposition of acðaÞ and the definition of v,
respectively, we can derive scðaÞ (Eq. 11), thereby facilitating the
calculation of the aforementioned weighted average.
acðaÞ¼ ð12mðaÞÞ3 scðaÞ1mðaÞ 3 dcðaÞ (9)
dcðaÞ¼vðaÞ 3 scðaÞ (10)
scðaÞ¼ acðaÞ
11 ðvðaÞ e 1Þ 3mðaÞ (11)
Data
For present purposes, this article takes a healthcare perspec-
tive, aligned with NICE’s brief. NICE is charged with appraising
cost-effective use, covering National Health Service procedures
and Personal and Social Services.25 Given that Personal and Social
Services does not cover all long-term care options, long-term care
data are not included. Average per-capita healthcare spending
data estimated by Asaria et al (2017) are used26; they used
administrative Hospital Episode Statistics data27 from 2011 along
with aggregate data on the number of general practitioner (GP)
visits in a year. These per-capita data are available for sex and each
age up until 851—an average for all ages above 84. Costs are
available for 3 sectors: inpatient care, outpatient care, and GP and
pharmaceutical spending (Fig. 1). The data are further smoothed
using cubic splines. For mortality data, 2011 statistics from theOffice of National Statistics are used,28 which provides population
and cause-of-death figures for England and Wales by age and sex.
Decedent-survivor cost ratios estimated by Howdon et al
(2018)23 are used to adjust for TTD. The authors used Hospital
Episode Statistics data from years 2005 to 2006 and 2011 to 2012.
Ratios are available for inpatients age 50 onward. It is assumed
that ages below 50 take the ratio provided for age 50. For
outpatient and GP/pharmaceutical expenditure, the decedent-
survivor ratio is assumed to be 1:1.Cases
Before delving into disease-specific cases, future unrelated
medical costs for the average person are estimated, using a hy-
pothetical intervention for which there are no intervention costs
and only future costs—for example, saving someone from a car
accident. This is applied to all ages and demonstrates the cost-
effectiveness ratio of saving a life. Here, saving someone’s life
has no future related medical costs. Average future unrelated
medical costs are summed for each age and divide by quality-
adjusted life-years (QALYs) gained. To calculate QALYs, we
multiply survival by quality-of-life estimates, from Heijink et al
(2011).29 They predict EuroQol 5-dimension scores by sex and age
using UK value sets. For all cases, discount rates of 3.5% for both
outcomes and costs are used, as recommended by NICE.
The first case based on existing research is osimertinib, a
medication used to treat non–small-cell lung carcinomas.30 The
study by Bertranou et al (2018) compares osimertinib to platinum-
based doublet chemotherapy in patients age 62 and above. It was
recommended by NICE in 2016, with a 1.54 QALY gain and a £41
705 per QALY ICER. The second case is the use of midostaurin, a
multitargeted protein kinase. In the study by Tremblay et al
(2018),31 midostaurin with the standard of care (SOC) is compared
to SOC for newly diagnosed acute myeloid leukemia adult patients
aged 48 years and above. There were life-year gains of 1.67 and
QALY gains of 1.47. It was recommended for reimbursement by
NICE in 2018 with ICERs of £30 263 per life-year and £34 327 per
QALY. The third case is the use of transcatheter aortic valve im-
plantation (TAVI) compared with medical management (MM). Van
Baal et al (2016)11 estimate survival curves from Watt et al
Figure 2. Average, survivor, and decedent individual medical costs (top) and saving a life at age a (bottom). Costs and outcomes in the
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1030 VALUE IN HEALTH AUGUST 2020(2012),32 who found an ICER of £16 100. They look at patients over
age 80 and find a QALY gain of 1.24. Transcatheter aortic valve
implantation was also recommended by NICE in 2017.
For the aforementioned cases, the original studies’ survival
curves were extracted. Comparator future unrelated medical costs
were subtracted from intervention future unrelated medical costs.
Unrelated costs are combined with survival curves, assuming a
starting age of 62 years for the osimertinib case,30 48 years for the
midostaurin case, and 80 years for the TAVI case, adjusting for
related costs (mentioned in the original literature) and TTD. By
dividing this difference in costs by the difference in QALYs, we are
left with the increase in the ICER.
In the osimertinib case, specific costs of end-of-life care are
provided; equation 7 can be used to estimate average related
costs. In the TAVI case, the comorbidity of diabetes mellitus (DM)
is adjusted for. Fifty-seven percent of patients who cannot un-
dergo surgery for aortic stenosis suffered from prohibitive
comorbidities. Studies have found that approximately 36% of those
who have received TAVI have DM,33 and that average costs for DM
in the United Kingdom are approximately £3500.34 Using this
information, DM-specific costs are calculated for this population
(by multiplying average costs by prevalence) before adding them
to unrelated medical costs. We assume that average UK costs are
transferable to England and Wales.
Costs per patient provided in our cases30,31 and prevalence
data for England and Wales from the UK Prevalence Project
(2015)35 are used for cancer prevalence, while the National Health
Service Health Survey for England 2017 is used for cardiovascular
disease prevalence.36 Population mortality rates for both of the
cancers in our cases were accessed from Cancer Research UK
(2016).37,38 For cardiovascular disease, 2014 mortality rates from
the British Heart Foundation Cardiovascular Mortality Statistics
are used.39Results
In this section, the case of saving a life is dealt with first. The
upper graphs in Figure 2 show average future medical costs by age
and sex, independent of disease. Average costs and estimateddecedent and survivor costs are displayed separately for men and
women. The figure shows that decedent costs are higher than
survivor costs at all ages, and that future medical costs increase
with age. Furthermore, survivor future medical costs deviate from
average future medical costs from age 80 onward, that is, when
mortality rates substantially increase. The lower graphs show the
change in future unrelated medical costs divided by the change in
LYG and QALYs when a life is saved for free at age a, for both sexes.
For example, saving a life at birth leads to an ICER of £1300 per
QALY while saving a life at age 80 gives an ICER of £8000 per QALY.
These graphs also show that adjusting for TTD has little impact on
the ICERs.
The differences among all 3 cases’ intervention and comparator
for both survival rates (top) and future unrelated medical costs
(bottom) are shown in Figure 3. For the osimertinib case, there is a
dramatic difference in survival in the first years between patients
who received the intervention and those who received the
comparator, peaking at approximately 0.6. In the midostaurin
case, the differences in survival are much smaller (~0.075) at the
beginning between intervention and comparator and the decline
in these differences is more drawn out. The difference in survival
between TAVI and MM is still substantial, peaking at approxi-
mately 0.3 at age 83. Looking at the lower 2 graphs shows the
difference in future unrelated medical costs between treatment
and comparator, either adjusted or unadjusted for TTD. For all
studies, the fact that survival in the treatment group is higher in
the first years after treatment means that decedent costs are
postponed by several years. This is shown clearly in Figure 3,
where unrelated costs are larger for the comparator in the early
years for TTD-adjusted estimates; lower survival means higher
expected decedent costs in the early years after treatment.
Table 1 shows the difference between ICERs, including future
medical costs where estimates are shown adjusted and unad-
justed for TTD and double-counting (ie, excluding population
average disease-specific costs from the estimate of unrelated
costs), once again discounted according to NICE guidelines. The
estimates are shown along with the reported change in LYG and
QALYs and the ratio between these 2 variables because this is a
further indicator of how large the impact of including future costs
will be.2 There is indeed an increase in all case ICERs. When
Figure 3. Difference in survival (top) and unrelated medical costs (bottom) for all 3 cases. Costs and outcomes were discounted
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HEALTH POLICY ANALYSIS 1031looking at the results when adjusted for TTD and double-counting,
the ICER comparing osimertinib with PDC increased by £5112
(12%), the ICER for midostaurin and SOC versus SOC increased by
£3167 (8%), and ICER for TAVI versus MM increased by £6345
(37%). In all cases, the difference in the ICERs resulting from
adjusting for double counting is modest. Table 1 also shows that
adjusting for TTD changes the ICER by between roughly £1000 and
£2507 in our cases. Furthermore, by adjusting for comorbidities,
TAVI costs increase by approximately an additional £1200
compared with only adjusting for TTD.Table 1. Difference in ICERs, adjusted for TTD and related costs.
Intervention Osimertinib vs
Age at start of intervention 62 years
Change in L (DL) 3.12
Change in QALY (D½L 3 Q ) 1.54










DCost/DQALY: including future costs £48 442 (5486
DCost/DQALY: including future costs,
adjusted for TTD
£47 191 (4235
DCost/DQALY: including future costs,
adjusted for TTD and comorbidity*
~
DCost/sDQALY: including future costs,
adjusted for double counting
£48 418 (5463
DCost/DQALY: including future costs,
adjusted for double counting and TTD
£47 225 (4269
DCost/DQALY: including future unrelated
costs, adjusted for double counting, TTD,
and comorbidity*
~
Note. Difference between actual and reported ICER shown in parentheses. Costs and
both costs and outcomes. Costs, including original ICERs, are adjusted for 2018 price
ICER indicates incremental cost-effectiveness ratio; L, life-years; MM, medical manag
year; SOC, standard of care; TAVI, transcatheter aortic valve implantation; TTD, time
*Only diabetes mellitus taken as a comorbidity.Discussion
This article has a dual purpose: first, to show that the inclusion
of unrelated healthcare costs can have potentially significant
policy-relevant implications for healthcare systems requiring a
systems perspective, and second, to demonstrate the feasibility of
a method of including them. In addition, given that economic
evaluations are conducted for a large variety of medical in-
terventions, it is beneficial to have a standardized approach to
including unrelated future medical costs. This article has providedPDC Midostaurin vs SOC TAVI vs MM




£38 033 £16 905
) £41 434 (3401) £24 736 (7831)
) £40 760 (2727) £22 379 (5474)
~ £23 578 (6673)
) £41 270 (3237) £24 076 (7171)
) £40 594 (2561) £22 308 (5403)
~ £23 507 (6602)
outcomes were discounted according to NICE guidelines—3.5% discount rate for
levels.
ement; PDC, platinum-based doublet chemotherapy; QALY, quality-adjusted life-
to death.
1032 VALUE IN HEALTH AUGUST 2020such an approach, along with a complementary online tool (http://
imta.shinyapps.io/PAIDUK). It shows the importance of future
unrelated medical costs being included in economic evaluation,
and the impact of adjusting the calculations to take TTD and
double counting into account.
By estimating the change in the ICER owing to hypothetically
saving a life at each age (Fig. 2), we see that including future
unrelated medical costs in economic evaluation leads to increases
in the ICER. For example, if we were to save the life of a man (or
woman) at age 75, the increase in the ICER due to unrelated future
costs would be around £7500 (£6250) per QALY, and these changes
to the ICER increase with age. These results mitigate the worry
that including future unrelated medical costs in economic evalu-
ation is particularly disadvantageous for diseases in children
because we find increases in the ICER resulting from including
these costs are lowest at the younger ages.
The results show that adjusting for double counting has a
modest impact on our results because the interventions exam-
ined affect relatively small subsets of the population. This
adjustment will be more important for public health in-
terventions affecting larger populations. Adjusting for TTD had a
substantial impact on the ICER in our case studies, with the
larger effects showing in older populations, where death is
relatively more expensive.
When comparing the 3 cases, there are a few further results
worth noting: First, it appears that the older the target group, the
larger the impact of including future unrelated medical costs.
Given that costs are highest at older ages, increased survival in
older target groups leads to comparatively higher differences in
future unrelated medical costs between treatment and interven-
tion. Second, in interventions with a target group with higher
future medical costs than the population average, adjusting for
relevant comorbidities leads to substantial increases in the ICER.
This is unsurprising given that additional (costly) comorbidities
will cause unrelated medical costs to increase. Third, the ratio of
change in LYG to change in QALYs is a further indicator of the
impact of including future costs—the larger the ratio, the larger
the impact. In other words, interventions where QALY gains were
primarily driven by life extensions were more affected by
including these costs than interventions were QALY gains were
driven by quality-of-life improvements.
Overall, including future unrelated medical costs appears to
have a considerable impact on the ICER. Given that reim-
bursement decisions are not based solely on cost-effectiveness
but on myriad factors, we cannot say with certainty that in-
creases in the ICER would influence specific reimbursement
decisions. Nevertheless, an increase of between 7% and 30% in
the ICER could be enough to change reimbursement decisions.
The fact that increases in the ICER are not of the same
magnitude among the cases used shows that including future
unrelated medical costs may lead to a shift in the hierarchy of
which interventions are viewed as most cost-effective, miti-
gating bias towards life-extending interventions. Our results are
presented in an online tool, in which our estimates of future
medical costs can be accessed and adjusted for specific in-
terventions, with options to adjust for TTD and double count-
ing of related costs.
There are limitations to our approach. First, average medical
costs are assumed to be the same for every person within an age
and sex group. Although this can be somewhat rectified by sub-
tracting related costs, there is the possibility that some patient
groups will have different unrelated future costs, for example, as a
result of being too weak for certain treatments. Second, the data
used have some restrictions, for example, decedent-survivor ratios
only being available from age 50 onward. Furthermore, these areaverage ratios, covering all inpatient expenditure. Wong et al22
show how drastically these ratios can differ from disease to dis-
ease in The Netherlands—for example, ratios at age 50 for lung
cancer and diabetes are approximately 1000 and 7, respectively.
The framework provided suggests adjusting for related costs
before TTD, independent of whether related end-of-life costs are
available, thereby assuming that the ratio of decedent-survivor
costs is the same for both average and related costs. Third, med-
ical expenditure data for England and Wales, compared with
similar data for The Netherlands, are low. Given that England and
Wales and The Netherlands spend comparable proportions of
their gross domestic product on healthcare, it can be assumed that
this is due to the collection of the data (bottom-up vs top-down)
and long-term care not being included in our estimations. Our
results for average unrelated future medical costs for England and
Wales are in line with similar work by Briggs et al (2018), sug-
gesting that these differences are country specific rather than
solely attributable to our study. Fourth, 2011 data are used as a
starting point for our costs, assuming that current spending pat-
terns remain constant over time. Finally, we do not explicitly
address the uncertainty around our estimates, which could stem
from either survival gains or unit costs. Going back to the con-
ceptual model presented in the Methods section, specifically
equation 1, the addition of unrelated medical costs per QALY to the
ICER can be written as D½ L 3 CuD½L 3Q  . Owing to life-years (L) being in
both the numerator and denominator, uncertainty surrounding
survival cancels out. Quality-adjusted life-years are provided by
the cases used, and therefore our main source of uncertainty is in
the unit costs themselves. As the original average costs are
calculated from population-wide data, uncertainty is of relatively
little concern here. Nevertheless, there are still sources of uncer-
tainty, specifically the age pattern of costs and decedent-cost ra-
tios. Estimating these ratios for England and Wales is beyond the
scope of this article; however, these are relevant and interesting
avenues for future research.
As this is the first work to present a standardized option for the
inclusion of future unrelated costs for England and Wales, there is
much future research to be considered. It may be beneficial to test
the assumption that during LYG, unrelated medical costs are equal
to per-capita average medical costs, using disease-specific patient
data. Furthermore, previous literature40 has provided an estimate
of the NICE cost-effectiveness threshold, using supply-side data.
They find marginal medical expenditure per QALY and suggest this
as a threshold for NICE. It would be worth estimating the impact of
the inclusion of future medical costs on this estimate because
excluding them would lead to inconsistency between ICER and
threshold estimates.
To conclude, this article provides an important methodological
contribution outlining how future unrelated medical costs can be
included in health technology assessment. It also demonstrates
how these methods apply for England and Wales and provides an
online tool for doing so in practice.Article and Author Information
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